Drugs News and Research

RSS

Obecure enters into licensing and clinical supply agreement with Grunenthal's subsidiary for XR betahistine

Obecure Ltd (http://www.obecure.com)., a subsidiary of Bio-Light Israeli Life Science Investments Ltd., announced today the execution of a licensing and clinical supply agreement with Farmaceutici Formenti SPA, the Italian Subsidiary of the Grunenthal Group.

17 Feb 2010

Study: Researchers use genomics to decode blueprint of Plasmodium falciparum

Scientists battling malaria have earned a major victory. According to a Nature Genetics study, an international group of researchers has used genomics to decode the blueprint of Plasmodium falciparum - a strain of malaria most resistant to drugs that causes the most deaths around the world.

17 Feb 2010

FDA approves risk management program on ESA's for treating anemia due to chemotherapy

The U.S. Food and Drug Administration today approved a risk management program to inform healthcare providers and their patients about the risks of a class of drugs called Erythropoiesis-Stimulating Agents (ESAs). For patients with cancer, the program is also designed to help ensure the appropriate administration of these drugs, which they receive to treat anemia that can occur as a result of chemotherapy.

17 Feb 2010

Idaho Health Freedom Act: Unproven, untried and vague, says AARP and urges Senate committee to reject bill

As Idaho families, businesses and retirees struggle with soaring health care costs, a vague bill aimed at tackling an issue in a non-existent federal health care law could make the crisis worse for many of the state's residents. The Idaho Health Freedom Act (HB 391) is set to be heard by Idaho Senate State Affairs Committee tomorrow morning, and AARP says the legislation is unproven, untried and vague and is urging them to reject the bill.

17 Feb 2010

Iowa State University researchers awarded 30 ARRA grants worth $16.38M

Iowa State University researchers have so far won 30 grants worth a total $16.38 million from federal agencies awarding money from the American Recovery and Reinvestment Act (ARRA).

17 Feb 2010

WebMD Health introduces new enhancements for Medscape Mobile for physicians

WebMD Health Corp., the leading source of health information, today announced a set of new enhancements for Medscape Mobile to assist physicians in diagnosis and treatment at the point-of-care. Medscape Mobile, WebMD's free medical application for physicians, now provides access to thousands of in-depth clinical reference articles on diseases, conditions, and procedures, in addition to complete reference information on over 7,000 brand name, generic and OTC medications.

17 Feb 2010

ACHF receives $2.5M as gift from KCCFA in support of childhood cancer research

The Alberta Children's Hospital Foundation received a gift of $2.5 million today from the Kids Cancer Care Foundation of Alberta in support of childhood cancer research at the Alberta Children's Hospital, as well as the Alberta Children's Hospital Research Institute for Child and Maternal Health and the Southern Alberta Cancer Research Institute - both at the University of Calgary.

17 Feb 2010

High-fat ketogenic diet safe and effective for controlling childhood seizures

Current and former patients treated with the high-fat ketogenic diet to control multiple, daily and severe seizures can be reassured by the news that not only is the diet effective, but it also appears to have no long-lasting side effects, say scientists at Johns Hopkins Children's Center.

17 Feb 2010

States struggle with insurance cost and coverage in Ohio, Rhode Island and Nebraska

The Columbus Dispatch reports that a health-insurance co-operative founded by Tom Rose, a retired businessman from Marietta, Ohio, "hopes to give people who feel alone in the health-care market that power-in-numbers feeling. ... Benefits Unlimited Inc. started in 2007 and started accepting dues-paying members across the nation last month. ... Annual dues range from $25 for an individual or household to $1,500 for employers or associations with 500 or more people.

17 Feb 2010

Rhubarb may have anti-cancer properties, but more research needed

Rhubarb contains natural chemicals called polyphenols that have been shown to kill cancer cells in the lab, or prevent their growth. Baking appears to greatly increase the levels of these chemicals, UK scientists have found, but Cancer Research UK cautioned against reading too much into these results.

17 Feb 2010

Researchers adopt new technique to inhibit cancer growth

One of the difficulties of fighting cancer is that drugs often hit other non-cancerous cells, causing patients to get sick. But what if researchers could sneak cancer-fighting particles into just the cancer cells?

17 Feb 2010

NanoViricides signs research and development agreement with Dr. Eva Harris’s laboratory at UC Berkeley

NanoViricides, Inc. (the "Company"), reports that it has signed a research and development agreement with Dr. Eva Harris’s laboratory at the University of California, Berkeley (UC Berkeley).

17 Feb 2010

New fluorescent probes improve tumor detection in mice

Building on his Nobel Prize-winning work creating fluorescent proteins that light up the inner workings of cells, a team of researchers led by Howard Hughes Medical Institute investigator Roger Tsien, PhD, professor of pharmacology, chemistry and biochemistry at the University of California, San Diego and the Moores UCSD Cancer Center has developed biological probes that can stick to and light up tumors in mice.

17 Feb 2010

Amgen and Centocor Ortho Biotech Products: FDA approves REMS for Aranesp, EPOGEN and PROCRIT ESAs

Amgen Inc. and Centocor Ortho Biotech Products, L.P., today announced that the U.S. Food and Drug Administration (FDA) has approved the Risk Evaluation and Mitigation Strategy (REMS) for erythropoiesis-stimulating agents (ESAs), which include Aranesp® (darbepoetin alfa), EPOGEN® (Epoetin alfa) and PROCRIT® (Epoetin alfa).

17 Feb 2010

Embera NeuroTherapeutics establishes clinical development partnership for its cocaine dependence program

Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for drug dependence, smoking cessation and obesity, announced today that the company has retained Exponential Pharma Ventures LLC to assist in establishing a clinical development partnership for its cocaine dependence program with a fully integrated pharmaceutical company.

17 Feb 2010

Chemists adopt new approach to optimise enzyme for practical applications

Engineers are unlikely to tinker with the cooling system if they want to increase the size of an engine. Yet chemists at the Max Planck Institute for Coal Research have adopted an approach similar to this in their efforts to optimise an enzyme for practical applications. They

16 Feb 2010

Researchers use model organism to test new therapies for retinal degeneration

Research by Johns Hopkins sensory biologists studying fruit flies, has revealed a critical step in fly vision. Humans with problems in this same step suffer retinal dystrophies, which manifest as visual defects ranging from mild visual impairments to complete blindness.

16 Feb 2010

Eat 'heart-healthy' oats to prevent atherosclerosis

Nutritionist Mohsen Meydani, director of the Vascular Biology Laboratory at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University in Boston, Mass., led the research on the oat compounds, called avenanthramides. Meydani previously has shown that phenolic antioxidants in oats obstruct the ability of blood cells to stick to artery walls.

16 Feb 2010

Fourth-quarter and full-year 2009 results announced by Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders, today announced financial and operational results for the fourth quarter and full year ended December 31, 2009.

16 Feb 2010

Oncolytics Biotech receives U.K. MHRA approval for REOLYSIN combination Phase 3 trial

Oncolytics Biotech Inc. today announced that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. This is the same trial that the Company previously reached an agreement on with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process.

16 Feb 2010

Drugs News and Research

Obecure enters into licensing and clinical supply agreement with Grunenthal's subsidiary for XR betahistine

Study: Researchers use genomics to decode blueprint of Plasmodium falciparum

FDA approves risk management program on ESA's for treating anemia due to chemotherapy

Idaho Health Freedom Act: Unproven, untried and vague, says AARP and urges Senate committee to reject bill

Iowa State University researchers awarded 30 ARRA grants worth $16.38M

WebMD Health introduces new enhancements for Medscape Mobile for physicians

ACHF receives $2.5M as gift from KCCFA in support of childhood cancer research

High-fat ketogenic diet safe and effective for controlling childhood seizures

States struggle with insurance cost and coverage in Ohio, Rhode Island and Nebraska

Rhubarb may have anti-cancer properties, but more research needed

Researchers adopt new technique to inhibit cancer growth

NanoViricides signs research and development agreement with Dr. Eva Harris’s laboratory at UC Berkeley

New fluorescent probes improve tumor detection in mice

Amgen and Centocor Ortho Biotech Products: FDA approves REMS for Aranesp, EPOGEN and PROCRIT ESAs

Embera NeuroTherapeutics establishes clinical development partnership for its cocaine dependence program

Chemists adopt new approach to optimise enzyme for practical applications

Researchers use model organism to test new therapies for retinal degeneration

Eat 'heart-healthy' oats to prevent atherosclerosis

Fourth-quarter and full-year 2009 results announced by Vanda Pharmaceuticals

Oncolytics Biotech receives U.K. MHRA approval for REOLYSIN combination Phase 3 trial

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News